$403 Million
Joint Bookrunner
Follow-On
September 2017
$375 Million
Joint Bookrunner
Follow-On
August 2017
Undisclosed
Exclusive Financial Advisor
Royalty Restructuring Transaction
August 2017
$330 Million
Exclusive Financial Advisor
Senior Credit Facilities Transaction with PNC & TCP
August 2017
$57 Million
Joint Bookrunner
Follow-On
August 2017
$86 Million
Joint Bookrunner
Follow-On
August 2017
$80 Million
Exclusive Financial Advisor
Acquisition of Exclusive WW Lebrikizumab License from Roche
August 2017
$138 Million
Joint Bookrunner
Initial Public Offering
August 2017
$40 Million
Exclusive Financial Advisor
Acquisition of Good Start Genetics
July 2017
$73 Million
Placement Agent
PIPE
July 2017
$116 Million
Joint Bookrunner
Follow-On
July 2017
$223 Million
Exclusive Financial Advisor
Private Placement
July 2017